Merck and Pfizer commence Phase III trial of ovarian cancer drug avelumab
Merck and Pfizer have commenced the JAVELIN Ovarian 100 Phase III trial of avelumab combined with platinum-based chemotherapy to treat locally advanced or metastatic disease (Stage III or Stage IV) with an untreated epithelial ovarian cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - July 7, 2016 Category: Pharmaceuticals Source Type: news

Merck and Pfizer initiate Phase III trial to evaluate Avelumab as first-line treatment for ovarian cancer
Merck KGaA, Darmstadt, Germany, and Pfizer (NYSE: PFE) have announced the initiation of a Phase III study, JAVELIN Ovarian 100, to evaluate the efficacy and safety of avelumab* in combination with, and/or as follow-on (maintenance) treatment to, platinum-based chemotherapy in patients with locally advanced or metastatic disease (Stage III or Stage IV) with previously untreated epithelial ovarian cancer. (Source: World Pharma News)
Source: World Pharma News - July 7, 2016 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Mechanisms & therapeutic targets of microRNA-associated chemoresistance in epithelial ovarian cancer
(Bentham Science Publishers) This review provides an overview of current therapeutic targets of miRNA-associated chemoresistance in EOC and illustrates the therapeutic potential and molecular mechanisms by which miRNAs influence the development and reversal of chemoresistance. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 16, 2016 Category: Cancer & Oncology Source Type: news

Ovarian Cancer Patients Being Left UntreatedOvarian Cancer Patients Being Left Untreated
Almost 20% of women with epithelial ovarian cancer do not undergo surgery, and nearly one-quarter of elderly women are not treated at all, researchers have found. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 13, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Debiopharm begins Phase II trial of IAP inhibitor Debio 1143 to treat EOC
Swiss-based biopharmaceutical company Debiopharm has begun the clinical Phase II trial to evaluate the company’s inhibitor of apoptosis proteins (IAP) inhibitor, Debio 1143, to treat epithelial ovarian cancer (EOC). (Source: Drug Development Technology)
Source: Drug Development Technology - June 7, 2016 Category: Pharmaceuticals Source Type: news

Scientists use modelling to show the role of metabolism and signaling in cancer metastasis
Researchers have built a model to investigate the metastasis of cancer by examining the metabolism of breast epithelial cells and look at the role of signaling. This research may contribute to the development of cell specific anti-cancer interventions. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 7, 2016 Category: Science Source Type: news

Scientists use modelling to show the role of metabolism and signaling in cancer metastasis
(PLOS) Researchers have built a model to investigate the metastasis of cancer by examining the metabolism of breast epithelial cells and look at the role of signaling. This research, published in PLOS Computational Biology, may contribute to the development of cell specific anti-cancer interventions. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 7, 2016 Category: Global & Universal Source Type: news

Answer revealed to this top-missed USMLE Step 2 question
Getting ready for the United States Medical Licensing Examination® (USMLE®) Step 2 is no easy feat, but we’re sharing expert insights to help give you a leg up. Take a look at the exclusive scoop on this month’s most-missed USMLE Step 2 test prep question. Think you have what it takes to rise above your peers? Test your USMLE knowledge, and view an expert video explanation of the answer from Kaplan Medical. Once you’ve got this question under your belt, be sure to test your knowledge with other posts in this series. Ready. Set. Go. This month’s question that stumped most students: A 42-year-old woman come...
Source: AMA Wire - May 25, 2016 Category: Journals (General) Authors: Troy Parks Source Type: news

Hormone Therapy Safe After Ovarian CancerHormone Therapy Safe After Ovarian Cancer
Hormone therapy use after treatment for nonserous epithelial ovarian cancer was not tied to reduced overall survival, and may have extended disease-free survival in women younger than 55 years. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 20, 2016 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news

[Special Issue Perspective] A collective route to metastasis: Seeding by tumor cell clusters
We present a model of metastatic dissemination that highlights the activities of clusters of tumor cells that retain and require their epithelial properties. Authors: Kevin J. Cheung, Andrew J. Ewald (Source: ScienceNOW)
Source: ScienceNOW - April 7, 2016 Category: Science Authors: Kevin J. Cheung Source Type: news

Controlling cell turnover in the intestinal lining
The lining of the intestine is the most rapidly-renewing tissue in the body. Routine shedding of epithelial cells from this lining is a key element of tissue turnover, and is thus essential to maintaining optimal health. Altered shedding is associated with multiple disorders, ranging from inflammatory bowel disease to colorectal cancer. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 5, 2016 Category: Science Source Type: news

Controlling cell turnover in the intestinal lining
(Children's Hospital Los Angeles) The lining of the intestine is the most rapidly-renewing tissue in the body. Routine shedding of epithelial cells from this lining is a key element of tissue turnover, and is thus essential to maintaining optimal health. Altered shedding is associated with multiple disorders, ranging from inflammatory bowel disease to colorectal cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 5, 2016 Category: Global & Universal Source Type: news

What can Frizzled7 reveal about breast cancer development?
(Mary Ann Liebert, Inc./Genetic Engineering News) A new study shows that Frizzled7, a protein present on human breast epithelial cells and a component of the Wnt signaling pathway is uniquely controlled by the Notch signaling pathway, both of which play key roles in mammary gland formation and breast cancer development. Evidence supporting the potential ability to regulate Notch-mediated Wnt signaling by targeting the NOTCH3-FZD7signaling network is presented in the study published in Stem Cells and Development. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 5, 2016 Category: Cancer & Oncology Source Type: news

Mesothelioma Clinical Trial Explores Surgery with Immunotherapy
The Baylor College of Medicine in Houston has begun exploring the effectiveness of specific immunotherapy drugs in combination with aggressive surgery for patients with malignant pleural mesothelioma. The single-center, clinical trial has the potential to extend lives and alter the current multidisciplinary approach to treatment. “It will allow us to gain a much deeper understanding for how these drugs work with mesothelioma,” Dr. Bryan Burt, thoracic surgical oncologist at Baylor and primary trial investigator, told Asbestos.com. “There definitely could be a benefit [for the patients]. These drugs have proven ...
Source: Asbestos and Mesothelioma News - March 28, 2016 Category: Environmental Health Authors: Tim Povtak Tags: Research & Clinical Trials Source Type: news

New Mesothelioma Immunogene Clinical Trial Set to Launch
For more than a decade, pulmonologist Dr. Dan Sterman has believed immunotherapy would become the catalyst for major advancements in the treatment of malignant pleural mesothelioma. Today, he is closer than ever to proving that point. Sterman, director of pulmonary medicine at New York University, soon will help launch a multicenter clinical trial involving a powerful immunogene therapy combination that may change the way this deadly asbestos-related cancer is viewed. “I believe that immunotherapy will become the fourth pillar of treatment for mesothelioma (joining chemotherapy, radiation and surgery),” Sterma...
Source: Asbestos and Mesothelioma News - March 22, 2016 Category: Environmental Health Authors: Tim Povtak Tags: Research & Clinical Trials Source Type: news